VIVAN Life Sciences Blog
Cipla’s Stempeutics gets process patent for Stempeucel from Japan
Drug major Cipla today said its JV firm Stempeutics Research has received process patent from the Japan Patent Office for novel stem cell drug Stempeucel aimed at treatment of critical limb ischemia (CLI).
Stempeutics chief operating officer B N Manohar said: “The new patent strengthens our position in Japan, which have created an accelerated development path for stem cell therapies.”
The company is actively evaluating the potential for accelerated development of ..
